Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.

Name: Αlpha¹ Rigor Record — Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
Item: Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
Rating: 59
Author: Αlpha¹

Ochoge M, Futa AC, Umesi A, Affleck L, Kotei L, Daffeh B, Saidy-Jah E, Njie A, Oyadiran O, Edem B, Jallow M, Jallow E, Donkor SA, Tritama E, Abid T, Jones KAV, Mainou BA, Konz JO, Fix A, Gast C, Clarke E

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4★ (Strong), 0 critical, 2 high issues for “Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
StatisticsPrinted percentage does not match its own count (capped)−0.25★
ReportingKey resources partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.
No data or code availability links were detected to verify.

Problems surfaced4 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously designed and reported phase 3 RCT with strong scientific grounding, clear randomisation/blinding, documented ethics approvals, and a concrete data-sharing statement. The main weaknesses are minor reporting gaps: no statistical software is named, no CONSORT checklist is referenced, and there is a low-severity text-vs-table denominator discrepancy.

Both reviewers agreed on 7 of 8 dimensions; they diverged only on key resources (pass vs warn), which I resolved toward warn because statistical software is an applicable, unidentified resource. The statistics component recomputed only a subset (5 tests: 4 consistent, 1 text-vs-table denominator discrepancy); tests with threshold-only p-values or exact/resampling methods were not machine-verifiable and are neither confirmed nor refuted.

9 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks. 1 printed percentage that does not match its own count.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

Prior work is extensively cited (phase 1/2 trials in Belgium, Panama, Bangladesh; historical mOPV2 controls; Emergency Use Listing rollout data), with both strengths and the genetic-stability rationale acknowledged. The rationale linking the vaccine's engineered genetic stability to the need for licensure/prequalification data is explicit, and the trial is framed to address the gap of no prior African data. The Discussion notes limitations of prior work (e.g., lower immunogenicity in non-temperate settings) and contextualises the trial against them.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific foundation, citing the polio eradication context, the cVDPV2 threat, and prior nOPV2 phase 1/2 trials, and clearly links this to the trial's licensure objectives.

Evidence

direct quote[Introduction; Research in context]

“In clinical trials done in adults (ie, those aged 18–50 years) in Belgium, in infants (ie, those aged 18–22 weeks) and children (ie, those aged 1–4 years) in Panama, and newborns in Bangladesh, the vaccine has been shown to be well tolerated and safe.”